BAYER AG

🇩🇪Germany

Country: 🇩🇪Germany

Ownership: Public

Established: 1863-08-01

Employees: 99.7K

Market Cap: $30.1B

Website: http://www.bayer.com

Clinical Trials

Vericiguat Drug-drug Interaction Study With Isosorbite Mononitrate in Stable Coronary Artery Disease Patients

Phase 1

Completed

Conditions: Coronary Artery Disease

Interventions: Drug: Vericiguat (BAY1021189)
Drug: Placebo
Drug: Isosorbide mononitrate (ISMN)

First Posted Date: 2017-08-21

Last Posted Date: 2021-12-29

Lead Sponsor: Bayer

Target Recruit Count: 41

Registration Number: NCT03255512

Locations: 🇩🇪
Universitätsklinikum Heidelberg, Heidelberg, Baden-Württemberg, Germany
🇩🇪
Medizinische Einrichtungen der Universität Bonn, Bonn, Nordrhein-Westfalen, Germany
🇩🇪
SocraTec R&D GmbH, Erfurt, Thüringen, Germany

and more 3 locations

Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single and Multiple Oral BAY1101042 Tablet Doses in Healthy Male Subjects

Phase 1

Completed

Conditions: Healthy Volunteer

Interventions: Drug: BAY1101042
Drug: Placebo

First Posted Date: 2017-08-16

Last Posted Date: 2019-08-19

Lead Sponsor: Bayer

Target Recruit Count: 96

Registration Number: NCT03252002

Locations: 🇩🇪
CRS Clinical-Research-Services Mönchengladbach GmbH, Mönchengladbach, Nordrhein-Westfalen, Germany
🇩🇪
CRS Clinical Research Services Wuppertal GmbH, Wuppertal, Nordrhein-Westfalen, Germany

Food Effect, Oral & Intravenous Pharmacokinetics and Absolute Bioavailability of BAY1834845 Including Drug-drug Interaction With Methotrexate

Phase 1

Completed

Conditions: Inflammation

Interventions: Drug: BAY1834845
Drug: Methotrexate

First Posted Date: 2017-08-09

Last Posted Date: 2019-07-15

Lead Sponsor: Bayer

Target Recruit Count: 10

Registration Number: NCT03244462

Locations: 🇳🇱
PRAHealthSciences, Groningen, Netherlands

Real-world Dosing Patterns of Rivaroxaban in the United States

Completed

Conditions: Atrial Fibrillation

Interventions: Drug: Rivaroxaban (Xarelto, BAY59-7939)

First Posted Date: 2017-08-08

Last Posted Date: 2023-06-28

Lead Sponsor: Bayer

Target Recruit Count: 12507

Registration Number: NCT03242278

A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids

Phase 3

Terminated

Conditions: Uterine Fibroids

Interventions: Drug: Vilaprisan (BAY1002670)

First Posted Date: 2017-08-07

Last Posted Date: 2024-10-18

Lead Sponsor: Bayer

Target Recruit Count: 766

Registration Number: NCT03240523

Locations: 🇨🇦
Clinique OVO, Montreal, Quebec, Canada
🇱🇹
Private hospital and outpatient clinic "Kardiolita", Vilnius, Lithuania
🇭🇺
Debreceni Egyetem Klinikai Kozpont, Debrecen, Hungary

and more 136 locations

Drug-drug-interaction Study to Assess the Effect of Darolutamide on the Pharmacokinetics of Probe Substrates of CYP3A4 and P-gp in Healthy Male Volunteers

Phase 1

Completed

Conditions: Prostatic Neoplasms

Interventions: Drug: Dabigatran etexilate
Drug: Midazolam
Drug: BAY1841788 (darolutamide)

First Posted Date: 2017-08-02

Last Posted Date: 2018-11-06

Lead Sponsor: Bayer

Target Recruit Count: 15

Registration Number: NCT03237416

Locations: 🇩🇪
CRS Clinical-Research-Services Mannheim GmbH, Mannheim, Baden-Württemberg, Germany

Clinical Study to Evaluate the Pharmacokinetics, Safety, Tolerability and Pharmacodynamic Effects of a Single Oral 10 mg BAY1101042 Tablet Dose in Men and Woman With Renal Impairment and in Healthy Subjects

Phase 1

Completed

Conditions: Renal Impairment

Interventions: Drug: BAY1101042

First Posted Date: 2017-08-01

Last Posted Date: 2023-06-05

Lead Sponsor: Bayer

Target Recruit Count: 36

Registration Number: NCT03235076

Locations: 🇩🇪
CRS Clinical-Research-Services Kiel GmbH, Kiel, Schleswig-Holstein, Germany

A Study to Assess Disintegration of the New Aspirin Disintegrating Tablets

Phase 1

Completed

Conditions: Moderate Pain

Interventions: Drug: 500 mg acetylsalicylic acid (Aspirin, BAYE4465)
Drug: 1000 mg acetylsalicylic acid (Aspirin, BAYE4465)
Drug: 400 mg ibuprofen(Nurofen)
Drug: 400 mg ibuprofen (Dolormin Extra)

First Posted Date: 2017-07-21

Last Posted Date: 2018-06-06

Lead Sponsor: Bayer

Target Recruit Count: 12

Registration Number: NCT03225352

Locations: 🇬🇧
Bio-Images Research Ltd, Glasgow, Glasgow City, United Kingdom

A Study to Test the Safety of the Investigational Drug Selitrectinib in Children and Adults That May Treat Cancer

Phase 1

Completed

Conditions: Solid Tumors Harboring NTRK Fusion

Interventions: Drug: Selitrectinib (BAY2731954)

First Posted Date: 2017-07-12

Last Posted Date: 2024-10-30

Lead Sponsor: Bayer

Target Recruit Count: 81

Registration Number: NCT03215511

Locations: 🇩🇰
Rigshospitalet - Kræftbehandling, Copenhagen, Denmark
🇺🇸
Univ.of California-San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸
UCLA Jonsson Comprehensive Cancer Center, Los Angeles, California, United States

and more 26 locations

BAY 1902607: Single Dose Escalation, Safety and Tolerability, Pharmacokinetics, Bioavailability, Food Effect

Phase 1

Completed

Conditions: Clinical Trials, Phase I as Topic

Interventions: Drug: BAY1902607
Drug: Placebo

First Posted Date: 2017-07-11

Last Posted Date: 2019-05-14

Lead Sponsor: Bayer

Target Recruit Count: 72

Registration Number: NCT03212586

Locations: 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy